Amyris (AMRS) Misses Q1 EPS by 9c, Revenues Miss; Maintains FY20 Revenue Growth Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Amyris, Inc. Reports First Quarter 2020 Results
May 8, 2020 8:30 AM EDTEMERYVILLE, Calif., May 8, 2020 /PRNewswire/ --Â Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company in Clean Health and Beauty markets through its consumer brands and a top supplier of sustainable and natural ingredients, today announced financial results for its first quarter ended March 31, 2020.
